含铋剂的四联疗法和标准三联治疗幽门螺杆菌感染的疗效评估

Evaluation of Efficacy of Quadruple Therapy and Standard Triple Therapy Containing Bismuth in the Treatment of HP Infection

目的:探讨含铋剂的四联疗法和标准三联治疗幽门螺杆菌感染的临床效果。方法:对2016年2月到2018年2月期间治疗的患者进行抽样,对40例幽门杆菌感染患者进行分组,随机平均分组为三联治疗的对照组和四联治疗的观察组各20例。比较疗效及用药安全情况。结果:观察组成功率明显高于对照组(P<0.05),观察组患者发生用药不安全反应的发生率与对照组较低(P<0.05)。结论:相较于标准三联疗法,含铋剂四联疗法治疗幽门螺杆菌感染,能显著提升疗效,未见严重不良反应,安全可靠,具有积极推广价值。

Objective:To investigate the clinical effect of bismuth-containing quadruple therapy and standard triple therapy in the treatment of helicobacter pylori infection.Method:The method of comparative efficacy observation was used to sample the patients treated from February 2016 to February 2018,and 40 patients with pylori infection were divided into groups,including the control group with triple treatment and the observation group with quadruple treatment with 20 cases each.Comparison of efficacy and safety.Results:The observed component power was significantly higher than that of the control group(P<0.05),and the rate of unsafe drug reactions in the observation group was lower than that in the control group,with no difference between groups(P<0.05).Conclusion:Compared with standard triple therapy,bismuth-containing quadruple therapy for helicobacter pylori infection can significantly improve the efficacy,with no serious adverse reactions,safe and reliable,and has positive promotion value.